Moderna, Inc.
MRNAModerna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
Drugs in Pipeline
43
Phase 3 Programs
17
Upcoming Catalysts
10
Next Catalyst
This month
Market Overview
Stock performance and key metrics
12 upcoming, 1 past
How MRNA's past catalysts played out
mRNA-1010
Seasonal Influenza
mRNA-1273
SARS-CoV-2
mRNA-1083
COVID-19
Influenza Vaccine
SARS-CoV-2
mRNA-1273.211
SARS-CoV-2
Fluarix®
Seasonal Influenza
mRNA-1345
Respiratory Syncytial Virus
Investigational mRNA-1273.815
SARS-CoV-2
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Seasonal Influenza
mRNA-4157
Personalized Cancer Vaccine
Melanoma
Fluzone HD
Respiratory Syncytial Virus
mRNA-1283
COVID-19
Fluarix Tetra
Seasonal Influenza
mRNA-1403
Acute Gastroenteritis
mRNA-1273.214
SARS-CoV-2
mRNA-1283.222
COVID-19
mRNA-1018-H5
Influenza
Egg-based Quadrivalent Influenza Vaccine
Influenza
mRNA-1195
Multiple Sclerosis
mRNA-1011.1
Seasonal Influenza
mRNA-1405
Norovirus Acute Gastroenteritis
Biological: mRNA-1273
SARS-CoV-2
mRNA-1975
Lyme Disease
Influenza Vaccine 1
SARS-CoV-2
mRNA-2808
Relapsed or Refractory Multiple Myeloma
mRNA-1982
Lyme Disease
mRNA-1189
Epstein-Barr Virus Infection
Pembrolizumab
Advanced Solid Tumors
mRNA-1647
Cytomegalovirus Infection
mRNA-1030
Seasonal Influenza
mRNA-1769
Smallpox
mRNA-1608
Genital Herpes
mRNA-1018 for H5N8
Influenza
mRNA-3927
Propionic Acidemia
mRNA-1073
SARS-CoV-2
mRNA-1283.211
SARS-CoV-2
Active Comparator
Seasonal Influenza
mRNA-1468
Herpes Zoster
mRNA-1893
Zika Virus
mRNA-1083 Composition 1 Dose A Lot A
Influenza
mRNA-3705
Methylmalonic Acidemia
mRNA-3745
Glycogen Storage Disease
mRNA-1010.4
Influenza
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
mRNA-1010 | Phase 3 | Seasonal Influenza | Fast Track | - |
mRNA-1273 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1083 | Phase 3 | COVID-19 | - | - |
Influenza Vaccine | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1273.211 | Phase 3 | SARS-CoV-2 | - | - |
Fluarix® | Phase 3 | Seasonal Influenza | - | - |
mRNA-1345 | Phase 3 | Respiratory Syncytial Virus | - | - |
Investigational mRNA-1273.815 | Phase 3 | SARS-CoV-2 | - | - |
Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine | Phase 3 | Seasonal Influenza | - | - |
mRNA-4157 Personalized Cancer Vaccine | Phase 3 | Melanoma | OrphanFast TrackBreakthrough | - |
Fluzone HD | Phase 3 | Respiratory Syncytial Virus | - | - |
mRNA-1283 | Phase 3 | COVID-19 | Fast Track | - |
Fluarix Tetra | Phase 3 | Seasonal Influenza | - | - |
mRNA-1403 | Phase 3 | Acute Gastroenteritis | - | - |
mRNA-1273.214 | Phase 3 | SARS-CoV-2 | - | - |
mRNA-1283.222 | Phase 3 | COVID-19 | - | - |
mRNA-1018-H5 | Phase 3 | Influenza | - | - |
Egg-based Quadrivalent Influenza Vaccine | Phase 2 | Influenza | - | - |
mRNA-1195 | Phase 2 | Multiple Sclerosis | - | - |
mRNA-1011.1 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1405 | Phase 2 | Norovirus Acute Gastroenteritis | - | - |
Biological: mRNA-1273 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1975 | Phase 2 | Lyme Disease | - | - |
Influenza Vaccine 1 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-2808 | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
mRNA-1982 | Phase 2 | Lyme Disease | - | - |
mRNA-1189 | Phase 2 | Epstein-Barr Virus Infection | - | - |
Pembrolizumab | Phase 2 | Advanced Solid Tumors | - | - |
mRNA-1647 | Phase 2 | Cytomegalovirus Infection | - | - |
mRNA-1030 | Phase 2 | Seasonal Influenza | - | - |
mRNA-1769 | Phase 2 | Smallpox | - | - |
mRNA-1608 | Phase 2 | Genital Herpes | - | - |
mRNA-1018 for H5N8 | Phase 2 | Influenza | - | - |
mRNA-3927 | Phase 2 | Propionic Acidemia | - | - |
mRNA-1073 | Phase 2 | SARS-CoV-2 | - | - |
mRNA-1283.211 | Phase 2 | SARS-CoV-2 | - | - |
Active Comparator | Phase 2 | Seasonal Influenza | - | - |
mRNA-1468 | Phase 2 | Herpes Zoster | - | - |
mRNA-1893 | Phase 2 | Zika Virus | - | - |
mRNA-1083 Composition 1 Dose A Lot A | Phase 2 | Influenza | - | - |
mRNA-3705 | Phase 2 | Methylmalonic Acidemia | - | - |
mRNA-3745 | Phase 2 | Glycogen Storage Disease | - | - |
mRNA-1010.4 | Phase 2 | Influenza | - | - |
COVID-19
1 drug in this indication
Seasonal Influenza
1 drug in this indication
Melanoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Moderna, Inc.'s drug pipeline?→
CatalystAlert tracks 43 drug candidates in Moderna, Inc.'s (MRNA) pipeline across Phase 3, Phase 2. Its lead program is mRNA-1010 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Moderna, Inc.'s next FDA catalyst?→
Moderna, Inc.'s (MRNA) next tracked catalyst is a Phase 2 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRNA biotech catalysts?→
Add MRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moderna, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.